Importance of the study of hemostasis and coagulation of thromboembolic diseases
Main Article Content
Abstract
The frequency of the thromboembolic disease is high in our populatíon. Several risk factors have been identified as favoring the development of thrombosis, such as: age, obesity, hypertension, diabetes, immobilization, estro gen therapy, sepsis, cancer, smoking, lipid diets, varicose veins. The ultimate cause of these events is arteriosclerosis in the arteries, phlebitis in the veins, that produce the formation or migration of clots in the circulation due to hypercoagulation , inflammation and lipid metabolic disorders. Even though the clínical features depend on the affected organ the treatment ís the same, consisting in anticoagu1ant therapy. Our results place emphasis in the importance on studdíng the parameters of hypercoagulation. We found Hypercoagulation in 83% of the cases, along or combine with inflammation in 45.5% or lipid metabolic disorders in 45.7%. Further data is stated in the paper
Downloads
Download data is not yet available.
Article Details
How to Cite
1.
Cañizares C. Importance of the study of hemostasis and coagulation of thromboembolic diseases. REMCB [Internet]. 2017Aug.8 [cited 2024Jul.3];27(1-2):7-14. Available from: https://remcb-puce.edu.ec/remcb/article/view/188
Section
Artículos Científicos
References
MARCUS, A.J. Thrombosis, and ínflamationas multicellular prosses: pathophysiologic significance of transcellular metabolism. Blood 1990; 76: 1903-1907
BADIMON, I. Endotelio, tmmbosis y arteriosclerosis. Rev. Iberoamer. Tromb. Hemoslasis. 1998; 11 (Suplemen- to 1): 38-41
BADIMON, I.; MRRINO, A.; BADIMOIst, J.J. Trombosis arterial y activación plaquetaria. Fisiopatologfa. Rev Ibe- roamer. Tromb. Hemostasisl992; 4: 75-80
ROSENDAAL, F,R.; MLMERHORST, F.M,; VADEN-BROUCKE, J.P. Oral contraceptics, horinon replacement thempy and thrombosis. Thromb. Haemost. 2001; 86:112- 123
ROUVIER, J.; SCAZZIOTA, A. Factores y marcadores de riesgo trombótico. Rev. Iberoamer. Trombo, Hemostasis 1994; 7: 192-209
LAZZARI, M.A. Marcadores trombííticos. Epidemiologfa de factores de reísgo pertenecientes al sistema de hemosta- sia. CLAHT. Simposium Internacional. Río de Janeiro, 16-17 de julio 1998: 47-50
FENSTEIN, D.; GREEN, D.; FEDERICO, A.B.; GOODNIGHT, Jr. S.H. Diagnosis and management of patients with spontaneously adquired inhibitors of coagulation. Hematology 1999. American Society of Hematology. Educational Program Book. New Oeleans, 3-7 December 1999, 192-205
DAVIS, M.; HAGEN, RO. The vascular endothelium. A new horizon. Ann. Surger. 1993; 218: 593-609
LOWE, G.D.; FORBES, C.D. Blood rheology and thrombosis. Clinics in Haematology. Thrombosis. Prentice CRM. W.B. Saunder, London 1981; 10: 343-367.
KROLL, M.H.; HELLMUMS, J.D.; MCINTIRE, L.V.; SCHAFER A. MONK, E.J. Platelets and shear stress. Blood 1996; 88: 1525-1541
ULUTIN, T.; UCYSIK, N.; HAYTAM, C.; KMOKAK, K.; SUIJUYBEK, G.; ULKII, B, As a fibrinolytic system indicator. Plasma tPAfPAI-1 complex in patients with coronary artery diacase. XIII th. Meeting of the International Society of Hematology (European & Africa division) Abstracs Book. Instanbul Türkiye. 3-8 September 1995, 997
CAÑIZARRS, C. La hemostasia. Las Plaquetas FUN- DACYT. Quito, 1997, 11-17
SCHAFER, A.I. Focussíng of the clot. Normal and patho- logic mechanisms. Ann. Rev. Med. 1987; 38: 211-220
FUSTER, V. Progression-regression of atherosclerosis molecular cellular and clinical bases. Circulation 1992; 86 (suppl. 111): 123
BAUER, K.A.; GOODNIGHT, M.D.; RIDKER, P.M. Hy- percoaguble. Translocauon of risk factor to clinical practice. Hematology 1998 American Society of Hematology. Education Program Book. Miami, 4-8 December, 255-273
YACOVALCA, T.; ALTER, M. Antiacoagulant for venous thromboembolism., what are the current options?. Post- grad. Med. 2000; 108: 43-46, 51-54
IUA FE , A.; CUENCA, J.; PASALODOS, J.A. Cirugía de revascularización miocárdica yfo trombolisis. Rev. Iberoa- mer. Tromb. Hemostasis. 1994; 7: 174-175
WEITZ, J.I.; MIDDELDORP, S.; GEERTS, W.; HEIT, J.A. Thrombophilia and New anticoagulant drugs. Hematology 2004. American Society of Hematology. Education Program Book. San Diego, California 4-7 December 2004, 434-438
MAHAFFEY, K.; FERGUSON, J. American College of Cardiology 2004 Scientific Sessions 2004
OLSSON, S.B. Executive Steering Committee on behalf of the SPORTIF IH Investigators. Stioke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): a randomized controlled trial. Laneet. 2003; 362: 169t-1698
HALPERIN, J.L. for the Executive Steering Committee on behalf of the SPORTIF V lnvesügators. Stroke Prevention Using the Oral Thrombin Inhibitor Ximelagatran in Patients with Nonvalvular Atrial Fibrillation V SPOR- TIF V. Program and abstracts from the American Heart Association Scientific Sessions 2003; November 9-12, 2003; Plenary Session VII: Late Breaking Clinical Trials.
WALLENTIN, L.; WILCOX, R.G.; WEAVER, W.D.; EMANUELSSON, H.; GOODVIN, A.; NYSTROM, P. y col; ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ES- TEEM randomized controlled trial. Lancet. 2003; 362: 789-797.
BROUWER, M.A.; VAN DEN BERGH, P.J.; AENGE- VAEREN, W.R.; VEEN, G.; LUUTEN, H.E.; HERTZ-
BERGER, D.P. y col. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the prevention of reocclusion in coronary thrombolysis (APRICOT)-2 trial. Cuculation 2002; 106: 659-665.
VAN ES, R.F.; JONKER, J.J.; VERHEUGT, F.W., DEC- KERS, J.W.; Grobbee DE; 360: 109-113.THE Clopidogrel in Unstable Angina to Prevent Recurrent Events, Trial Investigators. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. N Eng1 J Med 2001; 345: 494-502
COTTER, G.; SHEMESH, E.; ZEHAVI, M.; DINUR, I.; RUDNICK, A.; MILO, 0. y col. Lack of aspirin effect: Aspirin resistance or resistance to taking Aspirin? Am Heart J 2004; 147: 293-300
YORK, M.; AGARWAL, A.; EZEKOWITZ, M. Physicians’ attitudes and the use of oral anticoagulants: surveying the present and envisioning future. J Thromb Throm- bo1ysis,2003; 16: 33-37
MEZZANO, D.; LEIGTHON, F. Haemostatic Cardiovas- cular Risk Factors: Differential Effects of Red Wine and Dieton Healthy Young Population. Liga del Mediterr6- neo. Eslovenia, 2204
LANGE, R.A.; HILLIS, L.D. Concurrent antiplatelet and fibrinolytic therapy. New Eng J Med 2005; 352: 1248-
1250.
GRANT, P.J. The genetics of atherothrombosis disorders: a clinicians view. J. Thromb. Haemost. State of the Art 2003. XIX Congreso of the International Society on Th- rombosis and Haemostasis. 2003; 1: 1381-1390
BAUER, K.A. Update in thrombofilia. Hematology 1999; American Society of Hematology Education Program Book. New Orleans, 3-7 December 1999, 231-235
BADIMON, I. Endotelio, tmmbosis y arteriosclerosis. Rev. Iberoamer. Tromb. Hemoslasis. 1998; 11 (Suplemen- to 1): 38-41
BADIMON, I.; MRRINO, A.; BADIMOIst, J.J. Trombosis arterial y activación plaquetaria. Fisiopatologfa. Rev Ibe- roamer. Tromb. Hemostasisl992; 4: 75-80
ROSENDAAL, F,R.; MLMERHORST, F.M,; VADEN-BROUCKE, J.P. Oral contraceptics, horinon replacement thempy and thrombosis. Thromb. Haemost. 2001; 86:112- 123
ROUVIER, J.; SCAZZIOTA, A. Factores y marcadores de riesgo trombótico. Rev. Iberoamer. Trombo, Hemostasis 1994; 7: 192-209
LAZZARI, M.A. Marcadores trombííticos. Epidemiologfa de factores de reísgo pertenecientes al sistema de hemosta- sia. CLAHT. Simposium Internacional. Río de Janeiro, 16-17 de julio 1998: 47-50
FENSTEIN, D.; GREEN, D.; FEDERICO, A.B.; GOODNIGHT, Jr. S.H. Diagnosis and management of patients with spontaneously adquired inhibitors of coagulation. Hematology 1999. American Society of Hematology. Educational Program Book. New Oeleans, 3-7 December 1999, 192-205
DAVIS, M.; HAGEN, RO. The vascular endothelium. A new horizon. Ann. Surger. 1993; 218: 593-609
LOWE, G.D.; FORBES, C.D. Blood rheology and thrombosis. Clinics in Haematology. Thrombosis. Prentice CRM. W.B. Saunder, London 1981; 10: 343-367.
KROLL, M.H.; HELLMUMS, J.D.; MCINTIRE, L.V.; SCHAFER A. MONK, E.J. Platelets and shear stress. Blood 1996; 88: 1525-1541
ULUTIN, T.; UCYSIK, N.; HAYTAM, C.; KMOKAK, K.; SUIJUYBEK, G.; ULKII, B, As a fibrinolytic system indicator. Plasma tPAfPAI-1 complex in patients with coronary artery diacase. XIII th. Meeting of the International Society of Hematology (European & Africa division) Abstracs Book. Instanbul Türkiye. 3-8 September 1995, 997
CAÑIZARRS, C. La hemostasia. Las Plaquetas FUN- DACYT. Quito, 1997, 11-17
SCHAFER, A.I. Focussíng of the clot. Normal and patho- logic mechanisms. Ann. Rev. Med. 1987; 38: 211-220
FUSTER, V. Progression-regression of atherosclerosis molecular cellular and clinical bases. Circulation 1992; 86 (suppl. 111): 123
BAUER, K.A.; GOODNIGHT, M.D.; RIDKER, P.M. Hy- percoaguble. Translocauon of risk factor to clinical practice. Hematology 1998 American Society of Hematology. Education Program Book. Miami, 4-8 December, 255-273
YACOVALCA, T.; ALTER, M. Antiacoagulant for venous thromboembolism., what are the current options?. Post- grad. Med. 2000; 108: 43-46, 51-54
IUA FE , A.; CUENCA, J.; PASALODOS, J.A. Cirugía de revascularización miocárdica yfo trombolisis. Rev. Iberoa- mer. Tromb. Hemostasis. 1994; 7: 174-175
WEITZ, J.I.; MIDDELDORP, S.; GEERTS, W.; HEIT, J.A. Thrombophilia and New anticoagulant drugs. Hematology 2004. American Society of Hematology. Education Program Book. San Diego, California 4-7 December 2004, 434-438
MAHAFFEY, K.; FERGUSON, J. American College of Cardiology 2004 Scientific Sessions 2004
OLSSON, S.B. Executive Steering Committee on behalf of the SPORTIF IH Investigators. Stioke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): a randomized controlled trial. Laneet. 2003; 362: 169t-1698
HALPERIN, J.L. for the Executive Steering Committee on behalf of the SPORTIF V lnvesügators. Stroke Prevention Using the Oral Thrombin Inhibitor Ximelagatran in Patients with Nonvalvular Atrial Fibrillation V SPOR- TIF V. Program and abstracts from the American Heart Association Scientific Sessions 2003; November 9-12, 2003; Plenary Session VII: Late Breaking Clinical Trials.
WALLENTIN, L.; WILCOX, R.G.; WEAVER, W.D.; EMANUELSSON, H.; GOODVIN, A.; NYSTROM, P. y col; ESTEEM Investigators. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ES- TEEM randomized controlled trial. Lancet. 2003; 362: 789-797.
BROUWER, M.A.; VAN DEN BERGH, P.J.; AENGE- VAEREN, W.R.; VEEN, G.; LUUTEN, H.E.; HERTZ-
BERGER, D.P. y col. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the prevention of reocclusion in coronary thrombolysis (APRICOT)-2 trial. Cuculation 2002; 106: 659-665.
VAN ES, R.F.; JONKER, J.J.; VERHEUGT, F.W., DEC- KERS, J.W.; Grobbee DE; 360: 109-113.THE Clopidogrel in Unstable Angina to Prevent Recurrent Events, Trial Investigators. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. N Eng1 J Med 2001; 345: 494-502
COTTER, G.; SHEMESH, E.; ZEHAVI, M.; DINUR, I.; RUDNICK, A.; MILO, 0. y col. Lack of aspirin effect: Aspirin resistance or resistance to taking Aspirin? Am Heart J 2004; 147: 293-300
YORK, M.; AGARWAL, A.; EZEKOWITZ, M. Physicians’ attitudes and the use of oral anticoagulants: surveying the present and envisioning future. J Thromb Throm- bo1ysis,2003; 16: 33-37
MEZZANO, D.; LEIGTHON, F. Haemostatic Cardiovas- cular Risk Factors: Differential Effects of Red Wine and Dieton Healthy Young Population. Liga del Mediterr6- neo. Eslovenia, 2204
LANGE, R.A.; HILLIS, L.D. Concurrent antiplatelet and fibrinolytic therapy. New Eng J Med 2005; 352: 1248-
1250.
GRANT, P.J. The genetics of atherothrombosis disorders: a clinicians view. J. Thromb. Haemost. State of the Art 2003. XIX Congreso of the International Society on Th- rombosis and Haemostasis. 2003; 1: 1381-1390
BAUER, K.A. Update in thrombofilia. Hematology 1999; American Society of Hematology Education Program Book. New Orleans, 3-7 December 1999, 231-235